Moffitt Cancer Center | Strategic Alliance Partners

July 12, 2021

David Sallman, MD, discusses unmet needs in the treatment of patients with higher-risk myelodysplastic syndromes.

July 07, 2021

Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.

June 29, 2021

Kamran A. Ahmed, MD, discusses the need for multidisciplinary care in patients with HER2-positive breast cancer and leptomeningeal disease.

June 05, 2021

A single infusion of brexucabtagene autoleucel, a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

June 03, 2021

Bijal Shah, MD, MS, discusses shortcomings with BTK inhibitors in high-risk mantle cell lymphoma.

May 28, 2021

Novel immunotherapy combinations are gaining ground in the frontline treatment of patients with lung cancer, but the toxicities associated with these regimens must be weighed against the benefit they provide.

May 25, 2021

Jing-Yi Chern, MD, ScM, discusses future research directions in the treatment of patients with ovarian cancer.

May 25, 2021

Andrea Saltos, MD, provides perspective on the use of targeted therapy across EGFR-, RET-, and MET-positive NSCLC.

May 20, 2021

Bruna Pellini, MD, discusses the current state of treatment in ES-SCLC, the importance of including a diverse and representative patient population in clinical trials, and ongoing research in ES-SCLC.

May 19, 2021

Bruna Pellini, MD, discusses the challenges of using topotecan as a comparator arm for second-line clinical trials in extensive-stage small cell lung cancer.

May 04, 2021

Michael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

April 30, 2021

Andreas Saltos, MD, discusses the importance of broad molecular testing in non–small cell lung cancer.

April 09, 2021

Hye Sook Chon, MD, teases out some of the differences between the data with PARP inhibitors in the frontline maintenance setting and shed light on ongoing research with combinations that could broaden their utility in patients with advanced ovarian cancer.

March 31, 2021

HEPZATO KIT has demonstrated statistically significant benefit compared to best alternative care in patients with liver-dominant metastatic ocular melanoma, according to preliminary results from the phase 3 FOCUS trial.

March 30, 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

March 23, 2021

Jing-Yi Chern, MD, ScM, discusses the role of maintenance PARP inhibition in patients with recurrent platinum-sensitive ovarian cancer, as well as remaining questions regarding the utility of PARP inhibitors in this setting.

March 15, 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses the basis for combining chemotherapy, PARP inhibitors, and VEGF inhibitors with immunotherapy in ovarian cancer and ongoing research with ADCs in the field.

February 24, 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses novel immunotherapy combinations for the treatment of patients with ovarian cancer.

February 16, 2021

Jing-Yi Chern, MD, ScM, discusses efforts being made to combine PARP inhibitors with chemotherapy and immunotherapy in patients with recurrent ovarian cancer.

February 02, 2021

Patrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.